| scholarly article | Q13442814 |
| P50 | author | Jagpreet Chhatwal | Q47677602 |
| P2093 | author name string | Mark Roberts | |
| Fasiha Kanwal | |||
| Turgay Ayer | |||
| Xiaojie Wang | |||
| Qiushi Chen | |||
| Stefano Fagiuoli | |||
| Jorg Petersen | |||
| Emily Bethea | |||
| Yueran Zhuo | |||
| P2860 | cites work | Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 |
| Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance | Q27472758 | ||
| Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis | Q28552507 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India | Q33698956 | ||
| Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients | Q34415766 | ||
| The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries | Q34550098 | ||
| Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 | ||
| The changing burden of hepatitis C virus infection in the United States: model-based predictions. | Q35168083 | ||
| Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving | Q36138797 | ||
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study | Q38371502 | ||
| Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel | Q38812848 | ||
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm | Q39213684 | ||
| Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. | Q40072613 | ||
| Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals | Q40528873 | ||
| Profiles and clinical management of hepatitis C patients in Spain: disHCovery study | Q40880398 | ||
| Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis | Q42995849 | ||
| Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004. | Q43031120 | ||
| Assessment and proposal of a new combination of screening criteria for hepatitis C in France | Q43295179 | ||
| Trends in organ donation and transplantation in the United States, 1999-2008. | Q44125408 | ||
| Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. | Q45226069 | ||
| Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries | Q46904370 | ||
| The burden of illness associated with hepatocellular carcinoma in the United States. | Q51124738 | ||
| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 | ||
| Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer | Q56336688 | ||
| Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection | Q58324407 | ||
| The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat | Q58966386 | ||
| Assessing the cost-effectiveness of hepatitis C screening strategies in France | Q59352418 | ||
| Screening of hepatitis C virus infection in adult general population in Spain | Q59358200 | ||
| Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling | Q59360774 | ||
| EASL Recommendations on Treatment of Hepatitis C 2018 | Q88344766 | ||
| Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs | Q90210404 | ||
| P433 | issue | 6 | |
| P304 | page(s) | e026726 | |
| P577 | publication date | 2019-06-11 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study | |
| P478 | volume | 9 |
| Q99709743 | Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment |
| Q89805424 | Hepatitis C Virus Vaccine: Challenges and Prospects |
| Q90414520 | The Changing Epidemiology of Hepatocellular Carcinoma : Experience of a Single Center |
| Q89977599 | The Importance of Transaminases Flare in Liver Elastography: Characterization of the Probability of Liver Fibrosis Overestimation by Hepatitis C Virus-Induced Cytolysis |
Search more.